Literature DB >> 3995301

Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex.

R Quirion, J Richard, T V Dam.   

Abstract

Levels of serotonin type-2 receptors and choline acetyltransferase (ChAT) were measured in various rat brain regions following unilateral lesions of the nucleus basalis magnocellularis (nBM). As expected, lesions of the nBM markedly decrease cortical ChAT activity. Moreover, [3H]ketanserin (serotonin type-2) binding is significantly decreased in lamina IV of the anterior and middle cortex on the lesioned vs control side. [3H]ketanserin binding in the striatum is not affected by lesions of the nBM. Autoradiograms of [3H]ketanserin binding in lesioned animals show similar results. This suggests that at least a certain proportion of serotonin type-2 receptor binding sites are located on cholinergic terminals in lamina IV of the rat cortex. Therefore, further investigations on cholinergic-serotonergic interactions in the cortex and their possible involvement in senile dementia of the Alzheimer's type appear to be highly relevant.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995301     DOI: 10.1016/0006-8993(85)91590-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

2.  Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals.

Authors:  M Heider; R Schliebs; S Rossner; V Bigl
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

Review 3.  Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system.

Authors:  J G Chabot; S Kar; R Quirion
Journal:  Histochem J       Date:  1996-11

4.  Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.

Authors:  Catharine A Winstanley; Yogita Chudasama; Jeffrey W Dalley; David E H Theobald; Jeffrey C Glennon; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-02       Impact factor: 4.530

5.  Pharmacological analysis of conditioning in sensorimotor cortex neurons in a model.

Authors:  R A Chizhenkova
Journal:  Pavlov J Biol Sci       Date:  1989 Jan-Mar

6.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

7.  Similar ameliorating effects of benzomorphans and 5-HT2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors.

Authors:  K Matsuno; T Senda; K Matsunaga; S Mita; H Kaneto
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning.

Authors:  John A Harvey; Jennifer L Quinn; Reijun Liu; Vincent J Aloyo; Anthony G Romano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-17       Impact factor: 4.530

Review 9.  Role of the serotonin 5-HT(2A) receptor in learning.

Authors:  John A Harvey
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

10.  Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task.

Authors:  M Carli; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.